Tag: 苏州幻境spa正规吗

Very Strange That Instead Of Procuring Presence Of Accused, Magistrate Dismissed The Complaint: Allahabad HC [Read Order]

first_imgNews UpdatesVery Strange That Instead Of Procuring Presence Of Accused, Magistrate Dismissed The Complaint: Allahabad HC [Read Order] Akshita Saxena28 Sep 2020 2:18 AMShare This – xThe Allahabad High Court recently quashed an order of the Chief Judicial Magistrate, dismissing the complaint registered against a Sub-Inspector, after he failed to appear before the Court. “It is very strange that instead of procuring presence of the accused, the learned Magistrate dismissed the complaint,” the Bench of Justice KJ Thaker remarked while quashing the dismissal…Your free access to Live Law has expiredTo read the article, get a premium account.Your Subscription Supports Independent JournalismSubscription starts from ₹ 599+GST (For 6 Months)View PlansPremium account gives you:Unlimited access to Live Law Archives, Weekly/Monthly Digest, Exclusive Notifications, Comments.Reading experience of Ad Free Version, Petition Copies, Judgement/Order Copies.Subscribe NowAlready a subscriber?LoginThe Allahabad High Court recently quashed an order of the Chief Judicial Magistrate, dismissing the complaint registered against a Sub-Inspector, after he failed to appear before the Court. “It is very strange that instead of procuring presence of the accused, the learned Magistrate dismissed the complaint,” the Bench of Justice KJ Thaker remarked while quashing the dismissal order. The Bench observed that the non-presence of an accused should be sought to be procured by way of invoking procedure as per provisions of Section 87 (Issue of warrant in lieu of, or in addition to, summons) of the CrPC. However, in the present case, instead of following the procedure, the Magistrate dismissed the complaint. Holding the impugned order to be perverse, the Bench observed, “The learned Magistrate has the duty cast to see that there is no misuse of the Court proceedings. In this case, there is a clear misuse of process of law by the accused who even after coming to know that summons were issued against them and their revision were dismissed, did not appear before the Court below and strange enough the learned Magistrate dismissed that matter of the complainant at the stage of issuance of bailable warrant as accused had not appeared before it pursuant to the summons already issued. There was no question of affixing process fees and, therefore, the dismissal under Section 204 of Cr.P.C. is bad.” Background A practising advocate had filed a complaint under Section 200 of CrPC before the Chief Judicial Magistrate, Moradabad in the year 2012, about commission of offences under Section 379 (Theft), 504 (Intentional insult with intent to provoke breach of the peace) and 505 (Statements conducing to public mischief) of IPC. After recording of the complainant’s statement and that of the witnesses, the Court issued summons to the accused, one Jaibhagwan Singh, Sub Inspector. Against the summoning order, instead of appearing before the Court, the accused preferred a revision, which was rejected vide order dated 5.2.2018. Subsequently, the Judge even sent notices to the higher authorities to procure the presence of the accused but, in vain. Thereafter, the complainant fell sick and the judge dismissed the Complaint under Section 204(4) of CrPC (payment of process fee), vide order dated 13.8.2018. Findings The Court observed that the Respondent appears to be a “head strong police officer” who have not appeared before the Court since 2012, despite service of summons and dismissal of revision challenging the summoning order. It observed, “It is very strange that the learned Judge whose order is under challenge did not pass orders for procuring the presence of the accused.” It observed that since the summons was already issued, the requirement of process fee under Section 204(4) of CrPC was already complied with. In this backdrop the Court held that the Magistrate ought to have proceeded with the criminal case as the presence of the complainant was not at all necessary. It said, “Once the process fees has been affixed, it is the duty of the police authority through the Court to procure the presence of the accused unless orders otherwise are passed. xxx The order passed by the learned Judge below dismissing the case is absolutely cryptic. The stage was for appearance of the accused who was evading summons and was aware that summoning order was passed. The accused is shield by Superintendent of Police, Moradabad as after notice, no action is taken by him. The revision filed by the accused was also dismissed on 5.2.2018. All these factual aspect ought to have been taken care of by the Magistrate. At stage of seeking the presence of accused, the presence of the complainant was not at all necessary.” The Court has therefore ordered the Magistrate to forthwith deal with the accused and procure his presence, “even if it has to be procured by way of non bailable warrant to be served through Superintendent of Police.” Click Here To Download Order Read Order Subscribe to LiveLaw, enjoy Ad free version and other unlimited features, just INR 599 Click here to Subscribe. All payment options available.loading….Next Storylast_img read more

Novel protocol improves pancreatic cancer outcomes

first_img Broccoli and Brussels sprouts: Cancer foes Related Dietary link found to drug-resistant breast cancer Amino acid leucine, found in animal products and beans, blocks effectiveness of medications Locally advanced pancreatic cancer (LAPC) — a tumor that, while still confined to the pancreas, involves major abdominal blood vessels — is one of the worst forms of an already deadly tumor, as it cannot be removed surgically. Now a Massachusetts General Hospital (MGH) Cancer Center clinical trial of a treatment protocol combining intensive chemotherapy and radiation with the blood-pressure drug losartan has produced unprecedented results, allowing complete removal of the tumor in 61 percent of participants and significantly improving survival rates.“Around 40 percent of pancreatic cancer patients have either locally advanced or borderline resectable disease, with historically poor rates of successful surgery,” said Janet Murphy, an instructor in medicine in the hematology/oncology division of Mass. General’s Department of Medicine, co-lead and corresponding author of the report in JAMA Oncology. “To be able to successfully remove the primary tumor in 61 percent of patients sets a new benchmark and offers much hope. To our knowledge, this is the first LAPC clinical trial that defined surgical success as its primary outcome.”The most novel element of the trial — use of the antihypertension drug losartan — builds on the findings of co-author Rakesh K. Jain, director of the Steele Laboratories for Tumor Biology at MGH and Andrew Werk Cook Professor of Radiation Oncology at Harvard Medical School, and his colleagues. Those studies found that losartan, which targets the angiotensin signaling pathway, improved the delivery of chemotherapy drugs in animal models of breast, pancreatic, and ovarian cancer. It does so by relieving pressures in the tumor microenvironment that physically block drug delivery and reduce the supply of oxygen, which is required for the tumor-killing effects of radiation therapy. Those studies also found that cancer patients who happened to be taking losartan or similar drugs for hypertension tended to live longer than others receiving the same sorts of cancer therapies.From August 2013 through July 2017 the study enrolled 49 MGH Cancer Center patients with previously untreated LAPC. All participants received chemotherapy with a combination of fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFIRINOX) over a four-month period, during which they also took daily doses of losartan. After CT scan evaluation to determine whether blood vessels were still involved in the tumors, patients who no longer had vascular involvement received a short course of proton-beam radiation therapy, while those whose tumors still included major blood vessels had a longer course of conventional radiation therapy. Both groups received capecitabine chemotherapy during this period.After completing the chemoradiotherapy stage, 34 of the 49 participants were able to have their tumors removed, with 30 of those procedures successfully eliminating all evidence of cancer around the tumor. A pathologic complete response — which signifies no tumor found anywhere — was achieved for three patients. Analysis of circulating biomarkers throughout the course of the study found significant drops in the expression of TGF-β, a key element in the angiotensin-signaling pathway, indicating that losartan was having its desired effect. Both the time until recurrence and the overall survival time were significantly longer than what previously had been seen in LAPC patients.“A key part of the success of our approach was our surgeons’ willingness to attempt an operation even in patients who had the appearance of cancer at or near their blood vessels,” said Murphy. “We learned in a previous study, confirmed here, that CT scan results and resectability are no longer clearly correlated after chemotherapy and radiation. While we did not see total blood vessel clearance in 61 percent of patients, 61 percent achieved a complete removal of their cancer.” Co–lead author Jennifer Wo, an assistant professor of radiation oncology, adds, “Locally advanced pancreatic cancer has been generally considered an incurable disease, so these results mark a dramatic improvement with respect both to rates of conversion to surgical resectability and to long-term disease outcomes. Based on these results we have launched a new, multi-institutional clinical trial that will also include the immunotherapy drug nivolumab, since losartan treatment has also been shown to activate several immune-system pathways.”The co-senior authors of this report are Theodore Hong, MGH Radiation Oncology, and Carlos Fernández-del Castillo, MGH Department of Surgery.Support for the study includes a National Institutes of Health Proton Beam NCI/Federal Share Program grant and the National Cancer Institute’s Cancer Clinical Investigator Team Leadership Award. Research finds compound in such cruciferous vegetables that may help to suppress tumors last_img read more